CATX vs MNPR
CATX: A clinical-stage radiopharmaceutical company pioneering 212Pb-based alpha-emitter therapies and theranostics for precision oncology. MNPR: Monopar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oncology therapeutics, including novel radiopharmaceutical agents.
Side-by-side fundamentals
| Metric | CATX | MNPR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.71 | $83.98 | |
| Market cap | $309M | $564M | |
| ROE FY2025, SEC XBRL | -49.8% | -10.0% | MNPR higher |
| ROA FY2025, SEC XBRL | -38.6% | -9.7% | MNPR higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | MNPR lower |
| Revenue growth (YoY) as of 2026-09-03 | -58.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.56 | 1.53 | |
| 1-year return as of 2026-10-08 close | -29.8% | -14.8% | MNPR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.